Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …

Background and Objectives A recent report estimated that approximately 1 million adults
were living with multiple sclerosis (MS) in the United States. Although MS is rarely the direct …

Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug
intervention, with a view to modifying disease progression. Consequently, healthcare costs …

The editorial briefs about the issues of the Journal Annals of Neurology. The authors provide
a summary overview of the substantial current and future economic impact of neurological …

Abstract Background The Patient Determined Disease Steps (PDDS) is a promising patient-
reported outcome (PRO) of disability in multiple sclerosis (MS). To date, there is limited …

Objective: To examine the pricing trajectories in the United States of disease-modifying
therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences …

Costs of disorders of the brain in Europe EUROPEAN JOURNAL OF NEUROLOGY Volume 12,
Supplement 1, June 2005 Costs of Disorders of the Brain in Europe Guest Editors: Patrik …

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several
previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the …

Importance No current therapy for relapsing-remitting multiple sclerosis (MS) results in
significant reversal of disability. Objective To determine the association of nonmyeloablative …